Insights into the pharmaceuticals and mechanisms of neurological orphan diseases: current status and future expectations

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorRamalho, Teodorico C.-
Autor(es): dc.creatorCastro, Alexandre A. de-
Autor(es): dc.creatorTavares, Tássia S.-
Autor(es): dc.creatorSilva, Maria C.-
Autor(es): dc.creatorSilva, Daniela R.-
Autor(es): dc.creatorCesar, Pedro H.-
Autor(es): dc.creatorSantos, Lucas A.-
Autor(es): dc.creatorCunha, Elaine F. F. da-
Autor(es): dc.creatorNepovimova, Eugenie-
Autor(es): dc.creatorKuca, Kamil-
Data de aceite: dc.date.accessioned2026-02-09T12:30:00Z-
Data de disponibilização: dc.date.available2026-02-09T12:30:00Z-
Data de envio: dc.date.issued2019-03-29-
Data de envio: dc.date.issued2019-03-29-
Data de envio: dc.date.issued2018-10-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/33367-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0301008217302022#!-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1162524-
Descrição: dc.descriptionSeveral rare or orphan diseases have been characterized that singly affect low numbers of people, but cumulatively reach ∼6%–10% of the population in Europe and in the United States. Human genetics has shown to be broadly effective when evaluating subjacent genetic defects such as orphan genetic diseases, but on the other hand, a modest progress has been achieved toward comprehending the molecular pathologies and designing new therapies. Chemical genetics, placed at the interface of chemistry and genetics, could be employed to understand the molecular mechanisms of subjacent illnesses and for the discovery of new remediation processes. This review debates current progress in chemical genetics, and how a variety of compounds and reaction mechanisms can be used to study and ultimately treat rare genetic diseases. We focus here on a study involving Amyotrophic lateral sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Spinal muscular atrophy (SMA) and Familial Amyloid Polyneuropathy (FAP), approaching different treatment methods and the reaction mechanisms of several compounds, trying to elucidate new routes capable of assisting in the treatment profile.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceProgress in Neurobiology-
Palavras-chave: dc.subjectNeurological orphan disease-
Palavras-chave: dc.subjectAmyotrophic lateral sclerosis-
Palavras-chave: dc.subjectDuchenne muscular dystrophy-
Palavras-chave: dc.subjectSpinal muscular atrophy-
Palavras-chave: dc.subjectFamilial amyloid polyneuropathy-
Palavras-chave: dc.subjectDoença órfã neurológica-
Palavras-chave: dc.subjectEsclerose lateral amiotrófica-
Palavras-chave: dc.subjectDistrofia muscular de Duchenne-
Palavras-chave: dc.subjectAtrofia muscular espinhal-
Palavras-chave: dc.subjectPolineuropatia amilóide familiar-
Título: dc.titleInsights into the pharmaceuticals and mechanisms of neurological orphan diseases: current status and future expectations-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.